Guardado en:
| Autores principales: | Susanna Hallberg, Björn Evertsson, Ellen Lillvall, Malin Boremalm, Pierre de Flon, Yunzhang Wang, Jonatan Salzer, Jan Lycke, Katharina Fink, Thomas Frisell, Faiez Al Nimer, Anders Svenningsson |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2024
|
| Materias: | |
| Acceso en línea: | https://onlinelibrary.wiley.com/doi/10.1111/ene.16331 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
Rituximab treatment in pediatric‐onset multiple sclerosis
por: Markus Breu, et al.
Publicado: (2024)
por: Markus Breu, et al.
Publicado: (2024)
Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
por: F. Shawket, et al.
Publicado: (2026)
por: F. Shawket, et al.
Publicado: (2026)
Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease
por: Mezin Öthman, et al.
Publicado: (2024)
por: Mezin Öthman, et al.
Publicado: (2024)
Letter Concerning Comparative Safety Profiles of Ocrelizumab and Rituximab in MS Treatment
por: Anders Svenningsson, et al.
Publicado: (2025)
por: Anders Svenningsson, et al.
Publicado: (2025)
Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss
por: Simon Englund, et al.
Publicado: (2025)
por: Simon Englund, et al.
Publicado: (2025)
Novel Clinical Insights From a Swedish RFC1 Spectrum Disorder Cohort
por: Victor Alm, et al.
Publicado: (2026)
por: Victor Alm, et al.
Publicado: (2026)
Pattern of paresis in amyotrophic lateral sclerosis: A cohort study
por: Nan Hu, et al.
Publicado: (2024)
por: Nan Hu, et al.
Publicado: (2024)
Hospital‐Treated Infections and Risk of Disability Worsening in Multiple Sclerosis
por: Yihan Hu, et al.
Publicado: (2024)
por: Yihan Hu, et al.
Publicado: (2024)
HLA Associations of Intrathecal IgG Production against Specific Viruses in Multiple Sclerosis
por: Stephan Neidhart, et al.
Publicado: (2024)
por: Stephan Neidhart, et al.
Publicado: (2024)
Stable excess mortality in a multiple sclerosis cohort diagnosed 1970–2010
por: M.‐L. Sumelahti, et al.
Publicado: (2024)
por: M.‐L. Sumelahti, et al.
Publicado: (2024)
Early intensive therapy versus escalation strategy in French Caribbean multiple sclerosis cohort
por: Thomas David, et al.
Publicado: (2025)
por: Thomas David, et al.
Publicado: (2025)
Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein–Barr Virus in MS Development: A Presymptomatic Case–Control Study
por: Viktor Grut, et al.
Publicado: (2024)
por: Viktor Grut, et al.
Publicado: (2024)
Brain lesion characteristics in Chinese multiple sclerosis patients: A 7‐T MRI cohort study
por: Lei Su, et al.
Publicado: (2024)
por: Lei Su, et al.
Publicado: (2024)
Brain‐Derived Tau as an Outcome Marker in Guillain‐Barré Syndrome: A Retrospective Cohort Study
por: Brynhildur Hafsteinsdóttir, et al.
Publicado: (2025)
por: Brynhildur Hafsteinsdóttir, et al.
Publicado: (2025)
The influence of menopause on multiple sclerosis
por: Cecilia Smith Simonsen, et al.
Publicado: (2024)
por: Cecilia Smith Simonsen, et al.
Publicado: (2024)
Efficacy and safety of combined low‐dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy
por: Ying Du, et al.
Publicado: (2024)
por: Ying Du, et al.
Publicado: (2024)
Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple Sclerosis
por: Igal Rosenstein, et al.
Publicado: (2026)
por: Igal Rosenstein, et al.
Publicado: (2026)
Reply to “Letter to the Editor, Regarding ‘Intravenous Thrombolysis in Patients Taking Direct Oral Anticoagulation Treatment Before Stroke Onset: Results from the Safe Implementations of Treatments in Stroke International Stroke Registry’” recently Published by Matusevicius et al.
por: Marius Matusevicius, et al.
Publicado: (2025)
por: Marius Matusevicius, et al.
Publicado: (2025)
Reply to “Enhancing the Evaluation of IVT in DOAC‐Treated Stroke Patients: Addressing Methodological Considerations for Future Research”
por: Marius Matusevicius, et al.
Publicado: (2025)
por: Marius Matusevicius, et al.
Publicado: (2025)
The MMP ‐9/ TIMP ‐1 Ratio and Concentrations of Osteopontin Are Elevated in Cerebrospinal Fluid of People With Multiple Sclerosis and Decrease After Autologous Hematopoietic Stem Cell Transplantation
por: Ivan Pavlovic, et al.
Publicado: (2025)
por: Ivan Pavlovic, et al.
Publicado: (2025)
Longitudinal trajectories of digital upper limb biomarkers for multiple sclerosis
por: Yi Chao Foong, et al.
Publicado: (2024)
por: Yi Chao Foong, et al.
Publicado: (2024)
Circulating endocannabinoidome signatures of disease activity in amyotrophic lateral sclerosis
por: Raffaele Dubbioso, et al.
Publicado: (2024)
por: Raffaele Dubbioso, et al.
Publicado: (2024)
Loneliness as neurobehavioral issue in amyotrophic lateral sclerosis
por: Monica Consonni, et al.
Publicado: (2024)
por: Monica Consonni, et al.
Publicado: (2024)
Misfolded alpha‐synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment
por: Richard Smith, et al.
Publicado: (2024)
por: Richard Smith, et al.
Publicado: (2024)
Effect of autoimmune comorbidities on multiple sclerosis course: An observational multicenter study
por: Viviana Nociti, et al.
Publicado: (2024)
por: Viviana Nociti, et al.
Publicado: (2024)
Association between sun exposure habits and disease progression in multiple sclerosis
por: Jing Wu, et al.
Publicado: (2024)
por: Jing Wu, et al.
Publicado: (2024)
Croplands proximity is associated with amyotrophic lateral sclerosis incidence and age at onset
por: Umberto Manera, et al.
Publicado: (2024)
por: Umberto Manera, et al.
Publicado: (2024)
Association between CD20 + T lymphocytes and neuropsychological findings in multiple sclerosis
por: Antonio Esposito, et al.
Publicado: (2024)
por: Antonio Esposito, et al.
Publicado: (2024)
Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis
por: Daisuke Ito, et al.
Publicado: (2024)
por: Daisuke Ito, et al.
Publicado: (2024)
Rituximab in New‐Onset Generalized Myasthenia Gravis: Long‐Term Follow‐Up of the RINOMAX Clinical Trial
por: Jing Wu, et al.
Publicado: (2025)
por: Jing Wu, et al.
Publicado: (2025)
Correction to “Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with ATXN2 intermediate repeat expansions”
Publicado: (2025)
Publicado: (2025)
European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERNEURO‐NMD)
por: Philip Van Damme, et al.
Publicado: (2024)
por: Philip Van Damme, et al.
Publicado: (2024)
Education for fatigue management in people with multiple sclerosis: Systematic review and meta‐analysis
por: Maria Janina Wendebourg, et al.
Publicado: (2024)
por: Maria Janina Wendebourg, et al.
Publicado: (2024)
Elevated serum circulating cell‐free mitochondrial DNA in amyotrophic lateral sclerosis
por: Jieyu Li, et al.
Publicado: (2024)
por: Jieyu Li, et al.
Publicado: (2024)
Exploring amyotrophic lateral sclerosis through the visual system: A systematic review
por: Raoul K. Khanna, et al.
Publicado: (2024)
por: Raoul K. Khanna, et al.
Publicado: (2024)
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis
por: Pietro Iaffaldano, et al.
Publicado: (2024)
por: Pietro Iaffaldano, et al.
Publicado: (2024)
Proteomic signatures of physical, cognitive, and imaging outcomes in multiple sclerosis
por: Kian Jalaleddini, et al.
Publicado: (2024)
por: Kian Jalaleddini, et al.
Publicado: (2024)
Rituximab in secondary progressive multiple sclerosis: a meta‐analysis
por: Pasin Intarakhao, et al.
Publicado: (2024)
por: Pasin Intarakhao, et al.
Publicado: (2024)
Three‐dimensional magnetic resonance imaging of Baló‐like concentric lesion in multiple sclerosis
por: Kazunori Iwao, et al.
Publicado: (2024)
por: Kazunori Iwao, et al.
Publicado: (2024)
Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis
por: Jens Ingvarsson, et al.
Publicado: (2024)
por: Jens Ingvarsson, et al.
Publicado: (2024)
Ejemplares similares
-
Rituximab treatment in pediatric‐onset multiple sclerosis
por: Markus Breu, et al.
Publicado: (2024) -
Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
por: F. Shawket, et al.
Publicado: (2026) -
Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease
por: Mezin Öthman, et al.
Publicado: (2024) -
Letter Concerning Comparative Safety Profiles of Ocrelizumab and Rituximab in MS Treatment
por: Anders Svenningsson, et al.
Publicado: (2025) -
Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss
por: Simon Englund, et al.
Publicado: (2025)